Determinants of Weight Evolution Among HIV-Positive Patients Initiating Antiretroviral Treatment in Low-Resource Settings.

Huisin ʼt Veld, Diana; Balestre, Eric; Buyze, Jozefien; Menten, Joris; Jaquet, Antoine; Cooper, David A; Dabis, Francois; Yiannoutsos, Constantin T; Diero, Lameck; Mutevedzi, Portia; Fox, Matthew P; Messou, Eugene; Hoffmann, Christopher J; Prozesky, Hans W; Egger, Matthias; Hemingway-Foday, Jennifer J; Colebunders, Robert (2015). Determinants of Weight Evolution Among HIV-Positive Patients Initiating Antiretroviral Treatment in Low-Resource Settings. Journal of acquired immune deficiency syndromes JAIDS, 70(2), pp. 146-154. Lippincott Williams & Wilkins 10.1097/QAI.0000000000000691

[img]
Preview
Text
Huisin'tVeld JAcquirImmuneDeficSyndr 2015.pdf - Published Version
Available under License Publisher holds Copyright.

Download (241kB) | Preview

BACKGROUND In resource-limited settings, clinical parameters, including body weight changes, are used to monitor clinical response. Therefore, we studied body weight changes in patients on antiretroviral treatment (ART) in different regions of the world. METHODS Data were extracted from the "International Epidemiologic Databases to Evaluate AIDS," a network of ART programmes that prospectively collects routine clinical data. Adults on ART from the Southern, East, West, and Central African and the Asia-Pacific regions were selected from the database if baseline data on body weight, gender, ART regimen, and CD4 count were available. Body weight change over the first 2 years and the probability of body weight loss in the second year were modeled using linear mixed models and logistic regression, respectively. RESULTS Data from 205,571 patients were analyzed. Mean adjusted body weight change in the first 12 months was higher in patients started on tenofovir and/or efavirenz; in patients from Central, West, and East Africa, in men, and in patients with a poorer clinical status. In the second year of ART, it was greater in patients initiated on tenofovir and/or nevirapine, and for patients not on stavudine, in women, in Southern Africa and in patients with a better clinical status at initiation. Stavudine in the initial regimen was associated with a lower mean adjusted body weight change and with weight loss in the second treatment year. CONCLUSIONS Different ART regimens have different effects on body weight change. Body weight loss after 1 year of treatment in patients on stavudine might be associated with lipoatrophy.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Pre-clinic Human Medicine > Institute of Social and Preventive Medicine

UniBE Contributor:

Egger, Matthias

Subjects:

600 Technology > 610 Medicine & health
300 Social sciences, sociology & anthropology > 360 Social problems & social services

ISSN:

0894-9255

Publisher:

Lippincott Williams & Wilkins

Language:

English

Submitter:

Doris Kopp Heim

Date Deposited:

11 Feb 2016 15:19

Last Modified:

10 Sep 2017 08:36

Publisher DOI:

10.1097/QAI.0000000000000691

PubMed ID:

26375465

BORIS DOI:

10.7892/boris.77264

URI:

https://boris.unibe.ch/id/eprint/77264

Actions (login required)

Edit item Edit item
Provide Feedback